SAR CoV-2 is an important group of animal and human pathogens that infect respiratory tract, hepatic, gastroenterological, and nervous systems of mouse, bat, bat, humans and other vertebrates. Middle East Respiratory Syndrome (MERS) and severe acute respiratory syndrome (SARS) Outbreaks in 2002–2003 have demonstrated the possibility of human to human transmission, animals to humans transmission of the emerging SARS-CoV-2. The World Health Organization (WHO) On 12 January 2020 renamed novel coronavirus infectious disease (COVID-19) to SARS-CoV-2 In late 2019, the first case of the COVID-19 was reported. A total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO in March 1, 2020. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host and by proxy has a zoonotic propensity. Angiotensin-converting enzyme 2 (ACE2) is the same receptor been used by the novel coronavirus as that of SARS-CoV and largely spreads through the respiratory tract. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress on the transmission mode dynamics and viral shedding in provide direction for isolation protocol. R0 estimates for SARS have been reported to range between 2 and 5, which is within the range of the mean R0 for COVID-19 found in this review. Due to similarities of both pathogen and region of exposure, this is expected. On the other hand, despite the heightened public awareness and impressively strong interventional response, the COVID-19 is already more widespread than SARS, indicating it may be more transmissible.
Part of the book: Some RNA Viruses